Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cedazuridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA known ✓ | P32320 | 11/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cedazuridine SCHEMBL13828324 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL10070522 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL10069553 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL23227281 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL172256 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL24807958 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL10070136 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL25286013 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL19965745 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL19965746 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303609-A1 | 2′-DEOXY-2′,2′-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230271996-A1 | PROCESS FOR PREPARING CEDAZURIDINE | SCINOPHARM TAIWAN, LTD. (TW) | 2023-08-31 | — | — | US | disclosed |
| US-20220411457-A1 | 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-12-29 | — | — | US | disclosed |
| US-11028119-B2 | Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-06-08 | — | — | US | disclosed |
| US-20200123189-A1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-04-23 | — | — | US | disclosed |
| US-20180072768-A1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072768-A1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-9834576-B2 | Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-05 | — | — | US | disclosed |
| US-9834576-B2 | Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-05 | — | — | US | disclosed |
| US-9567363-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-8951987-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8951987-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140186335-A1 | Certain Compounds, Compositions and Methods | EISAI INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140186335-A1 | Certain Compounds, Compositions and Methods | EISAI INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8268800-B2 | Certain compounds, compositions and methods | EISAI INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268800-B2 | Certain compounds, compositions and methods | EISAI INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2207786-B1 | 2'-FLUORO-2'-DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS | EISAI INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123189-A1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | DHFR, DHODH, DPYD | CDA 107/4885PDE4D 1130/4885PDE3A 3494/4885 |
| US-20140186335-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | CDA 134/4885PDE4D 907/4885PDE3A 944/4885 |
| US-20220411457-A1 | 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME | DCTD, DUT, DHODH | CDA 75/4885PDE4D 230/4885PDE3A 1942/4885 |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | DUT, TYMP, DPYD | CDA 134/4885PDE4D 907/4885PDE3A 944/4885 |
| US-20230271996-A1 | PROCESS FOR PREPARING CEDAZURIDINE | DUT, CCNB1, EZH1 | CDA 87/4885PDE4D 2766/4885PDE3A 2941/4885 |
| US-20090137521-A1 | Certain Compounds, Compositions and Methods | DUT, TYMP, DPYD | CDA 134/4885PDE4D 907/4885PDE3A 944/4885 |
| US-11028119-B2 | Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines | DHFR, DPYD, DHODH | CDA 82/4885PDE4D 920/4885PDE3A 3383/4885 |
| US-20230303609-A1 | 2′-DEOXY-2′,2′-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME | DCTD, DUT, DHODH | CDA 67/4885PDE4D 226/4885PDE3A 1987/4885 |
| US-20180072768-A1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | DHFR, DHODH, DPYD | CDA 107/4885PDE4D 1130/4885PDE3A 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.